Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-12-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SPECIFIC AIMS:

* To reverse hyperglycemia and insulin dependency in patients with Type 1 diabetes mellitus by islet cell transplantation.
* To induce a state of donor specific tolerance and eliminate the need for continuous immunosuppressive therapy by simultaneous transplantation of donor bone marrow cells with islets and utilization of the monoclonal antibody Campath-1H for induction of Immunosuppression.
* To assess long-term function of successful islet cell transplants in patients with Type 1 diabetes mellitus.
* To determine whether the natural history of the microvascular, macrovascular and neuropathic complications are altered following successful transplantation of islet

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen

NCT00021801

Type 1 Diabetes Mellitus

COMPLETED PHASE2

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

NCT00315627

Type 1 Diabetes Mellitus

COMPLETED PHASE2

Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression

NCT00306098

Diabetes Mellitus, Type I

COMPLETED PHASE2

Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression

NCT00021788

Diabetes Mellitus, Type 1

COMPLETED PHASE2

Islet Cell Transplants for Diabetes

NCT00303134

Diabetes Mellitus, Type 1

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In our current protocol (IRB #2000/0024) the immunosuppressive regimen, comprised of induction with daclizumab and maintenance therapy with sirolimus and tacrolimus, has been combined with the infusion of CD34+ enriched donor bone marrow stem cells in an attempt to create a chimeric state and hence induce donor tolerance. This strategy was tested by evaluating graft survival following the removal of all immunosuppressive medication after one year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Islet Transplantation and Bone Marrow

Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.

Group Type EXPERIMENTAL

Islet Transplantation and Bone Marrow

Intervention Type BIOLOGICAL

Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Islet Transplantation and Bone Marrow

Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Islet type 1 DM Bone marrow

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients between 18 and 65 years of age
2. Patients with type 1 diabetes mellitus for more than 5 years duration
3. One or more of the following:

* Hypoglycemia unawareness - judged by history of blood sugars \<54 on glucometer without symptoms and/or hypoglycemic episodes requiring assistance from either family, glucagon administration or emergency services
* Poor diabetes control (HbA1c\>8% or \>2 visits/yr to hospital for treatment of ketoacidosis) despite intensive insulin therapy
* Progressive complications of type 1 diabetes mellitus
4. Body Mass Index (BMI) ≤26

Exclusion Criteria

1. Untreated proliferative diabetic retinopathy;
2. HbA1C \> 12%;
3. Insulin requirement \> 1.0u/kg/d
4. Stimulated or basal C-peptide \> 0.3 ng/ml
5. Creatinine clearance \< 60 and/or serum creatinine consistently \> 1.5mg/dl;
6. Macroalbuminuria \> 300mg albumin in 24 hours
7. Presence of panel reactive antibodies \> 20%;
8. Previous/concurrent organ transplantation (except failed islet cell transplantation);
9. Any medical condition requiring chronic use of steroids;
10. Malignancy or previous malignancy (except non-melanomatous skin cancer);
11. X-ray evidence of pulmonary infection;
12. Active infections;
13. Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis can be provided)
14. Active peptic ulcer disease,
15. Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound;
16. Serological evidence of HIV, HBV (HBsAg+ and/or HBcAb+ and/or HBsAb+ without evidence of vaccination), HTLV-1 or HCV;
17. Negative serology for Epstein Barr virus (EBV) or evidence of acute infection (IgM\>IgG);
18. Abnormal liver function test;
19. Anemia (hemoglobin \<12.0 g/dl);
20. Hyperlipidemia (fasting total cholesterol \>240mg/dl and/or fasting triglycerides \>200mg/dl and/or fasting LDL cholesterol\>140mg/dl);
21. Body Mass Index above 26 and/or weight \>80kg;
22. Prostate specific antigen (PSA) \> 4 ng/ml;
23. Unstable cardiovascular status (including positive stress echocardiography if \>age 35);
24. Active alcohol or substance abuse;
25. Sexually active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable);
26. Positive pregnancy test or intent for future pregnancy, or male subject's intent to procreate.
27. Any condition or any circumstances that makes it unsafe to undergo an islet cell transplant.
28. History of previous transplant or previous bone marrow infusion.
29. Persistent leucopenia (white blood cell count \<3,000/mm3

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No